Trials / Completed
CompletedNCT02164578
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 179 (actual)
- Sponsor
- GWT-TUD GmbH · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients. Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban | |
| DRUG | Aspirin |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-12-12
- Completion
- 2020-04-30
- First posted
- 2014-06-16
- Last updated
- 2023-11-07
- Results posted
- 2023-11-07
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02164578. Inclusion in this directory is not an endorsement.